glp·helper
glphelper.com/tirzepatide/ohio/columbus
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Columbus, OH

Verified Tirzepatide providers in Columbus, OH. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
41
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Ohio
40 of 40 shown

Find a Tirzepatide provider in Ohio.

Every entry is checked against the NPI registry and the Ohio medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Ohio city · /tirzepatide/ohio/{city}
§ 03Getting Tirzepatide in Ohio
40 providers · 4 metros

How a prescription works in Ohio.

You don’t have to leave Ohio to start. Because tirzepatide isn't a controlled substance, a Ohio-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you, or you can see one of the 40 local providers below in person. What you pay depends on your plan, not your zip code.

Telehealth
Available in Ohio
Tirzepatide (tirzepatide) is a GLP-1, not a controlled substance, so a Ohio-licensed clinician can assess you and prescribe over video, with no federal in-person-visit requirement.
Who can prescribe
OH-licensed clinicians
Any physician, nurse practitioner, or PA licensed in Ohio can prescribe Tirzepatide. The 40 providers below are checked against the NPI registry and the Ohio board.
Medicaid (weight loss)
Diabetes only
As of April 2026, Ohio Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Ohio’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Columbus

Columbus, Ohio has a population of 905,748 people. The adult obesity rate in Columbus is an age-adjusted estimate of 35.5%, 1.4 percentage points below the Ohio state rate of 36.9%. Diagnosed diabetes reaches 13.1% of adults in Columbus. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 26.5% of adults in Columbus.

of Columbus adults have obesity
35.5%
diagnosed diabetes
13.1%
no regular physical activity
26.5%

Age-adjusted estimates for Columbus, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossweight regain after stopping
§ 05Support around Tirzepatide in Columbus
4 nutritionists

The prescription is one part. Here is the rest, in Columbus.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Columbus, OH, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Nan Criner, RN, BSN, CDE
NUTRITIONIST
Nutritionist · Education
4825 Knightsbridge Blvd
Call 614-459-0216NPI 1295869105
Abdulakdir Hassan
NUTRITIONIST
Nutritionist · Education
3353 Cleveland Ave Ste 76
Call 614-632-1222NPI 1437979549
Katherine Rapp, MNT
NUTRITIONIST
Nutritionist · Education
1180 E. Main Street
Call 614-645-5535NPI 1710066782
Deborah Tirpak, RD, LD
NUTRITIONIST
Nutritionist · Education
543 Taylor Ave
Call 614-257-5583NPI 1790895084

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Crunch Fitness - Reynoldsburg
GYM
4.3 on Google · 1143 reviews
5929 E Main St
Website
LA Fitness
GYM
3.5 on Google · 1130 reviews
850 Goodale Blvd
Website
Planet Fitness
GYM
4.2 on Google · 981 reviews
3465 S High St
Website
Life Time - Easton
GYM
4.4 on Google · 930 reviews
3900 Easton Station
Website
Crunch Fitness - Hilliard
GYM
4.2 on Google · 908 reviews
3644 Fishinger Blvd
Website
LA Fitness
GYM
3.7 on Google · 802 reviews
5959 Old Hamilton Rd
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Ohio

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Ohio

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]